Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression. The drug made by Johnson & Johnson under the brand name Spravato passed final ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...

The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

“In October 2022, the developer informed me that he was working with H Mart, but the name could not be publicly ... mid-scale national franchise hotel brand to be approved by the village.” ...